In a report released on November 8, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Outset Medical (OM – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $3.68.
According to TipRanks, Singh Chadha is an analyst with an average return of -9.4% and a 27.15% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Boston Scientific, Stryker, and Outset Medical.
Currently, the analyst consensus on Outset Medical is a Moderate Buy with an average price target of $10.80, representing a 193.48% upside. In a report released on November 6, TD Cowen also assigned a Buy rating to the stock with a $9.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Outset Medical’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $36.04 million and a GAAP net loss of $44.05 million. In comparison, last year the company earned a revenue of $25.06 million and had a GAAP net loss of $43.84 million
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Outset Medical (OM) Company Description:
Outset Medical Inc is a medical technology company. The company has developed a machine, Tablo, which reduces the cost and complexity of dialysis.
Read More on OM:
- Outset Medical backs FY23 revenue view roughly $130M, consensus $132M
- Outset Medical reports Q3 adjusted EPS (71c), consensus (67c)
- Netflix downgraded, Applied Materials upgraded: Wall Street’s top analyst calls
- Outset Medical downgraded to Underperform from Buy at BofA
- Outset Medical price target lowered to $17 from $29 at RBC Capital
